Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 11/20 | 0.47 |
| ▸ | HRH1 | P35367 | 10/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282383 | 0.85 | GPR119 (0.59) | CCR3HRH1GPR119HRH3KCNH2 | |
| SCHEMBL2585041 | 0.84 | FFAR4 (0.53) | CCR3HRH1GPR119HRH3CCR5 | |
| SCHEMBL4140781 | 0.83 | HRH1 (0.64) | CCR3HRH1KCNH2 | |
| SCHEMBL5406049 | 0.83 | GPR119 (0.48) | CCR3HRH1GPR119HRH3CCR5 | |
| SCHEMBL5462103 | 0.81 | GPR119 (0.58) | CCR3HRH1GPR119HRH3KCNH2 | |
| SCHEMBL5190405 | 0.81 | HRH1 (0.51) | CCR3HRH1KCNH2 | |
| SCHEMBL5190427 | 0.80 | CCR3 (0.49) | CCR3HRH1KCNH2 | |
| SCHEMBL5414237 | 0.80 | GPR119 (0.52) | CCR3HRH1GPR119HRH3KCNH2 | |
| SCHEMBL4720822 | 0.80 | HRH1 (0.62) | CCR3HRH1GPR119HRH3KCNH2 | |
| SCHEMBL5191295 | 0.78 | CCR3 (0.47) | CCR3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1816123-A1 | Intermediates for the production of pharmaceutically active compounds | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1546130-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1546130-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029041-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | CCR3, CCR1, CCL11 | CCR3 1/4885HRH1 49/4885GPR119 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.